Podcast - Ironing Out the Data: Iron Deficiency in Heart Failure

CardioNerds Cofounder Dr. Amit Goyal, Chair of the CardioNerds Heart Failure Committee Dr. Jenna Skowronski, and Episode FIT Lead Dr. Shazli Khan discuss iron deficiency and its impact on heart failure with Dr. Robert Mentz, Chief of Heart Failure at Duke University and principal investigator of the HEART-FID trial. In this case-based discussion, they cover the diagnostic criteria of iron deficiency in heart failure, epidemiology, and strengths and limitations of different iron formulations.  They also review clinical trials examining the impact of iron deficiency on quality of life, heart failure hospitalizations, and mortality. Importantly, they stress the relevance of iron metabolism in heart failure, irrespective of the presence of anemia. They also discuss the approach to addressing outpatient management of iron in heart failure and future directions of research needed in this domain. 

This episode was created in collaboration with the Cardiometabolic Health Congress and is supported by an educational grant from American Regent.  All CardioNerds education is planned, produced, and reviewed by CardioNerds.

Target Audience

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Review the prevalence and clinical burden of iron deficiency in HF patients
  • Summarize current and emerging diagnostic approaches, including clinical decision support tools, aimed to optimize the early diagnosis of ID in patients with HF
  • Interpret data about the efficacy and safety of intravenous iron repletion for the treatment of iron deficiency in HF patients
  • Summarize the guideline recommendations for the treatment of iron deficiency in patients with HF
  • Select individualized treatment regimens to manage ID in HF patients, including the administration of intravenous iron
Course summary
Available credit: 
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Participation
Course opens: 
08/20/2024
Course expires: 
08/20/2025
Rating: 
0

Robert Mentz, MD (Expert Faculty)
Associate Professor of Medicine
Associate Professor in Population Health Sciences
Member in the Duke Clinical Research Institute

Amit Goyal, MD
CardioNerds Co-Founder

Jenna Skowronski, MD
CardioNerds HF Committee Chair

Shazli Khan, MD
Episode Lead

ESTIMATED TIME TO COMPLETE ACTIVITY
0.5 hour

EDUCATIONAL GRANT SUPPORT

Supported by an educational grant from American Regent.

JOINT PROVIDERSHIP STATEMENT
A picture containing text, clipart Description automatically generated

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC) and CardioNerds.  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

PHARMACY CONTINUING EDUCATION

PACE designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-24-207-H01-P. Type of activity: Application

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 0.5 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from August 20, 2024 through August 20, 2025.

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Successfully complete activity post-test(s)
  4. Complete the activity evaluation

You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org. For additional information about the accreditation of this activity, please visit https://partnersed.com

DISCLOSURES

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Mentz, faculty for this educational activity, discloses the following:

  • Consultant, Advisor, Speaker: American Regent, Vifor, Pharmacosmos, BI/Lilly
  • Researcher: Novartis, AstraZeneca

Dr. Amit Goyal, faculty for this educational activity, discloses the following:

  • Consultant, Advisor, Speaker: Novo Nordisk, Lexicon Pharmaceuticals, Illumina, Esperion, Pfizer
  • Other: Zoll lifevest

Dr. Jenna Skowronski, faculty for this educational activity, has no relevant financial relationships.

Dr. Shazli Khan, faculty for this educational activity, has no relevant financial relationships.

DISCLOSURE OF UNLABELED USE 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

DISCLAIMER 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Available Credit

  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.